Perbandingan Kadar Antioksi dan Total pada Kanker Serviks Stadium Lanjut Sebelum dan Setelah Kemoterapi
Abstract
Tujuan: Membandingkan kadar antioksidan total pada penderita kanker serviks stadium lanjut sebelum dan setelah kemoterapi.
Metode: Merupakan penelitian studi kohort prospektif yang dilakukan di Badan Layanan Umum (BLU) Rumah Sakit Wahidin Sudirohusodo Perawatan onkologi-ginekologi Lontara 4 bawah dan Unit Penelitian Rumah Sakit Perguruan Tinggi Negeri Universitas Hasanuddin. dari perode tanggal 1 Oktober 2019–30 September 2020. Sampel penelitian adalah semua penderita kanker serviks stadium lanjut yang memenuhi kriteria inklusi. Data yang diambil adalah data primer menggunakan questionnaire serta pemeriksaan kadar Anti Oksidan Total dengan metode ELISA. Data yang diperoleh dianalisis dengan menggunakan program komputer SPSS 25.0, Microsoft Excel dan Microsoft Word.
Hasil: Terdapat 34 orang sampel penelitian menderita kanker serviks stadium lanjut yang mendapatkan kemoterapi 3 seri. Stadium 2B memiliki perbedaan rerata antioksidan yang signifikan secara statistik. Tipe adenokarsinoma, jenis diferensiasi kategori sedang dan kategori tidak ada keterangan memiliki perbedaan kadar antioksidan yang signifikan secara statistik. Terdapat perbedaan rerata kadar antioksidan total antara sebelum dan sesudah dilakukan kemoterapi dengan p<0,05.
Kesimpulan: Terdapat penurunan bermakna kadar antioksidan total sebagai penanda stres oksidatif pada pasien kanker serviks stadium lanjut yang menjalani prosedur kemoterapi.
Comparison Total Antioxidant Levels in Patients with Advanced Cervical Cancer Prior and Post-Chemotherapy
Abstract
Purpose: Comparing total antioxidant levels in patients with advanced cervical cancer prior and post-chemotherapy.
Method: This is a prospective cohort study underwent at the Public Service Agency of Wahidin Sudirohusodo Hospital, Lontara 4 Bawah oncology-gynecology care and Research Unit of State University Hospital, Hasanuddin University from October 1st, 2019 to September 30th, 2020. The study sample being used was all patients with advanced cervical cancer who met the inclusion criteria. The data extracted were primary data using a questionnaire, as well as the examination of Total Anti-Oxidant levels using the ELISA method. The data obtained were analyzed further using a computer program SPSS 25.0, Microsoft Excel, and Microsoft Word.
Outcome: Approximately 34 study samples were suffering from advanced cervical cancer who undergone 3 series of chemotherapy. Stage 2B revealed a statistically significant difference in antioxidant level. The type of adenocarcinoma, the type of the moderate category differentiation, and the no description category had statistically significant differences in antioxidant levels. It was identified that there was a difference in the mean total antioxidant level between prior and post-chemotherapy with p < 0.05.
Conclusion: There was a significant decline in the total antioxidant levels to indicate a sign of oxidative stress in advanced cervical cancer patients who are undergoing chemotherapy procedures.
Key word: Antioxidant Levels, Advanced Cervical Cancer, Chemotherapy
Keywords
Full Text:
PDFReferences
Demirci S, Ozsaran Z, Celik HA, et.al. The interaction between antioxidant status and cervical cancer: a case control study. Department of Medical Biochemistry, Ege University Faculty of Medicine, Bornova, Turkey, 2011: 97; 290−295.
World Health Organization.Cancer (online). 2018. available at : www.who.int/mediacentre/fatsheets/fs29
Pusat data dan informasi, Situasi Penyakit Kanker. Buletin Pusat Data dan Informasi, Kemenkes RI, 2015.
Kementerian Kesehatan Republik Indonesia. Kanker Serviks. Pedoman Nasional Pelayanan Kedokteran. Komite Penanggulangan Kanker Nasional. Jakarta: Kementerian Kesehatan Republik Indonesia, 2018.
Murray RK, Granner DK, Rodwell VW. Biokimia Harper, (Andri Hartono). Edisi 27. Jakarta: EGC, 2009.
De Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worlwide study. The Lancet Oncology, 2010; 11(11).
De Boer MA, Vet JN, Aziz MF, et al. Human papillomavirus type 18 and other risk factors for cervical cancer in Jakarta, Indonesia. Int J Gynecol Cancer. 2006; 16: 1809−14.
Paramita S, Soewarto S, Widodo MA, Sumitro SB. High parity and hormonal contraception use as risk factors for cervical cancer in East Kalimantan. Med J Indones 2010; 19: 268−2 72.
Kirwan JM, Symonds P, Green JA, Tierney J, Col- lingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother and Oncol, 2003;68:217
Jhonsons, O’Dwyer P, Cisplatin and its analogue. In: Devita V, Hellmens, Rossenberg, editors. Cancres Principles and Practice oncology. 7th edition. Philadelphia. Lippincott., 2005: 344−54.
Petignat P, Roy M. Diagnosis and management of cervical cancer. BMJ. 2007; 335(7623).
Dayem AA, Choi HY, Kim JH, Cho SG. Role of oxidative stress in stem, cancer, and cancer stem cells. Cancer. 2010; 2:859−84.
Shanmugan, M., Kolanjiappan, K., Kayalvizhi, M., dan Sethupathy, S. Lipid Peroxidation and Antioxidant Atatus in Cervical Cancer Patient. The Journal of Biochemistry Molecular Biology and Biophysics. 2002; 6(3): 225−227.
Naidu MS, Suryakar AN, Swami SC, et al. Oxidative Stress and antioxidant status in cervical cancer patients. Indian J Clin Biochem. 2007; 22(2): 140−144.
DOI: http://dx.doi.org/10.24198/obgynia.v4i2.285
Refbacks
- There are currently no refbacks.
_CROSREF22.jpg)
